Corcept Therapeutics

NCT00752843

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

NCT00698022

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

NCT02014337

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

NCT03508635

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

NCT06094712

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

NCT03067376

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

NCT06094790

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

NCT03259542

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

NCT03258372

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

NCT03315338

First-in-human Study in Healthy Subjects

NCT03335956

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

NCT03442621

Relacorilant Food Effect Study in Healthy Subjects

NCT03457597

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03512548

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

NCT03540836

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

NCT03878264

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

NCT03877952

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

NCT03674814

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

NCT03877562

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

NCT06094725

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

NCT04249323

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

NCT04672499

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

NCT06094738

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

NCT04373265

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

NCT04672512

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

NCT04795479

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

NCT04994743

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

NCT05003713

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

NCT04990310

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

NCT05117489

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05553470

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05347979

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05712265

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

NCT06495944

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

NCT06928779

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

NCT06947304

Evaluation of Miricorilant on Liver Fat in Patients With MASLD